{
    "id": "dbpedia_6043_2",
    "rank": 71,
    "data": {
        "url": "https://www.sidra.org/events/research/pmfg/2024/",
        "read_more_link": "",
        "language": "en",
        "title": "PMFG 2024",
        "top_image": "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2022/02/cropped-Favicon.png",
        "meta_img": "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2022/02/cropped-Favicon.png",
        "images": [
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2022/02/Sidra-Medicine-Logo.svg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2022/02/Sidra-Medicine-Logo.svg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/06/PMFG_20241_-_Picutres_Only-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2022/09/MOPH-Ara_Eng-BG-300x118.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/24.png",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/06/PMFG_20241_-_10th_Anniversary_logo1.png",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/02/2023.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2023/03/2022.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2022/03/PMFG2021.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2022/02/Welcome-Message-Poster-e1648443685856.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Ammira-1.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Khalid-1.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Nicolas_Encina_.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/04/dr-wan-yue-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Raghib-Ali.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/chantal-mathieu-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/05/dr-manuela-battaglia-03.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/dr-carlos-bustamante-pmfg-2024-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/HUGO.png",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/1904.17-Logo-Image.png",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/chop-pmfg-2024-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/Logo-onWhite@3x.png",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/Msheireb-Museums-e1724650723417.png",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/FOE24-QFDS-EN-01-1.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2022/02/Event-Location.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/ankit-malhotra-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/dr-carlos-bustamante-pmfg-2024-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/dr-nicola-pmfg-2024-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/charles-lee-pmfg-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/robert-c-green-pmfg-2024-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/08/joanne-hackett-pmfg-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/tan-ee-shien-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/matthias-herrath-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/robert-c-green-pmfg-2024-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/zornita-stark-pmfg-2024-05.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/said-ismail-pmfg-2024-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/samih-alqawlaq-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/edison-liu-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/mitchell-stotland-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/paul-franks-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/emanuele-bosi-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/peter-goodhand-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/07/hakon-hakonarson-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/06/camillo-ricordi-sidra-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/06/farhan-naim-sidra-01.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/05/dr-manuela-battaglia-03.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Khalid-1.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/04/dr-wan-yue-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Dr.-Hamdi-Mbarek.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Dr.-Radja-Badji.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Haris.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Raghib-Ali.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Frangoul_Haydar.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Askar.png",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Ian.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Maha.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Dr.-Karolina-Kobus-photo.jpeg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Rulan.png",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Sahar-Daas-.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Alanoud.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Ammira-1.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Khalid-1.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/arash-rafil-04.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Samir-Gupta-2023.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/chantal-mathieu-02.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Portrait_SD.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Tawfeg_Ben_Omran.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Essam_photo_2018.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Mohammad_Yousuf_Karim.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Nicolas_Encina_.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Richard_Oram.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2024/03/Younes_Mokrab.jpg",
            "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2022/02/Sidra-Medicine-Logo-White.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2024-08-05T12:46:41+00:00",
        "summary": "",
        "meta_description": "Overview",
        "meta_lang": "en",
        "meta_favicon": "https://www.sidra.org/events/research/pmfg/2024/wp-content/uploads/2022/02/cropped-Favicon-32x32.png",
        "meta_site_name": "PMFG 2024",
        "canonical_link": "https://www.sidra.org/events/research/pmfg/2024/",
        "text": "Welcome to Precision Medicine and the Future of Genomics 2024 Summit\n\nWe are excited to welcome all participants, partners, and supporters to PMFG 2024 as we celebrate a decade of advancements in precision medicine. As Chairs of this year’s summit, we are proud to have Sidra Medicine led the first precision medicine symposium in the Middle East since 2014, growing it into a hub for innovators in healthcare.\n\nPMFG 2024 will be held from December 3-5, 2024, in Doha, focusing on Genomics for All, Precision Diagnostics, and Advanced Therapeutics. We look forward to insightful discussions and transformative collaborations. Thank you for joining us and see you in Doha!\n\nPMFG 2024 Summit Organizing Chairs\n\nDr. Ammira Al-Shabeeb Akil / Prof. Khalid Fakhro\n\nDr. Nicola Withers\n\nIllumina\n\nDr. Nicola has accumulated over 25 years’ experience in the field of clinical laboratory sciences and genomics. She has been employed by Illumina for 8 years and during that time has focused on market development. She is currently leading the market development team and focused on prenatal and genetic disease NGS applications across Asia Pacific, Middle East and Africa with a keen interest in Newborn Screening.\n\nDr. Nicola also spent over 10 years working in the areas of clinical chemistry, haematology and pathology with a focus on public health screening programs and clinical studies.\n\nDr. Charles Lee\n\nJackson Laboratory\n\nCharles Lee, PhD, DSc, FACMG made a revolutionary discovery in 2004 while serving as a member of Harvard Medical School’s faculty: Genes don’t always occur in two copies per cell. This finding uprooted the field of human genetics, leading to new genetic diagnostic tests and a better understanding of human disease and evolution. Lee’s academic impact stretches well beyond this discovery. He has written over 190 scientific publications that have been cited more than 100,000 times. In 2008, Lee became the youngest recipient of the Ho-Am Prize in Medicine. In 2013, he was chosen to be the inaugural scientific director of the Jackson Laboratory for Genomic Medicine. From 2017 to 2023, Lee served as president of the Human Genome Organization; and in 2023, he was inducted as a Fellow of the Korean Academy of Science and Technology. His contributions to the field of human genetics have been recognized by many organizations and institutions including the University of Alberta, Duke University, the Katholic University of Leuven, the American Association for Cancer Research and the American Association for the Advancement of Science. Lee currently holds the Robert Alvine Family Endowed Chair at The Jackson Laboratory.\n\nDr. Joanne Hackett\n\nIQVIA\n\nVice President and Head of Health System Services at IQVIA and previously was the Chief Commercial Officer at Genomics England\n\nDr Hackett is a clinical academic, entrepreneur, investor, and a strategic, creative visionair with global experience spanning successful start-ups to Fortune 500 companies. Aside from her curious passion for life and positivity, Joanne is known for building innovation, driving personalised medicine and leading through fast paced, complex changing ecosystems and integrations. Joanne's goal is to contribute to bringing the world novel, cost effective and simple health care solutions, and she is particularly keen on building the case for prevention, open science and citizen genomics. She has extensive global experience across academic, business and clinical institutions, and enjoys sharing her experiences with the Boards she sits on as well as companies she provides strategic advice to.\n\nJoanne has been publicly recognised for her relentless pursuit of revolutionising healthcare and has been named one of the top six Influential Leaders in Healthcare by CIO Look, the Accenture Life Science Leader of the year, Freshfields Top 100 Most Influential Women, One HealthTech Top 70 Women in the NHS, Pharmaceutical Market Europe’s 30 women leaders in UK healthcare and BioBeat Top 50 Women in Biotech Award. Joanne believes in human courage and perseverance against the odds, and demonstrates that positive change, whether in a company or in one’s personal life, can be carved out from even the greatest of trials. As a believer of ‘health = wealth’, Joanne is an internationally known yoga instructor.\n\nDr. Tan Ee Shien\n\nSingHealth\n\nClin A/Prof Tan Ee Shien is the Head of SingHealth-Duke Genomic Medicine Centre and the Head of Service and Senior Consultant for Genetics Service in KK Women’s and Children’s Hospital. She is also currently the Genomics Co-Lead, SingHealth Duke-NUS Maternal and Child Health Research Institute. She is the Deputy Chief Medical Officer of the national precision medicine program, PRECISE. She started her training in Paediatrics in KK Women’s and Children’s Hospital in 2000 and obtained her MRCPCH in 2002. She then pursued her interest in genetics and was awarded the Health Manpower Development Plan fellowship in 2005. Her passion is to ensure that all patients with genetic diseases have access to the best care available.\n\nShe was also the Director of the National Newborn Screening Program in Singapore from 2011 till 2023. In this role, she has spearheaded the expansion of the repertoire of disorders tested during the newborn period.\n\nClin A/Prof Tan is actively involved in education and was the Paediatric clerkship director for the Duke NUS Graduate Medical School. She is a clinical associate professor in Duke GMS and YLL SOM and is a strong believer in mentoring the next generation.\n\nShe was also awarded Clinician Scientist Award 2009-2011 and is still involved in many research projects within the Genetics Service.\n\nDr. Matthias Herrath\n\nNovo Nordisk®\n\nDr. Matthias von Herrath, MD, is a distinguished physician-scientist with a remarkable reputation in immunology and drug development for type 1 diabetes. He has a strong background in academic medical research and the pharmaceutical industry, particularly in clinical translation of immune-based interventions for autoimmune and metabolic diseases.\n\nCurrently, Dr. von Herrath is the Scientific Director of the Diabetes Research Institute (DRI), University of Miami School of Medicine. In this role, he spearheads innovative research aimed at delaying, preventing, and ultimately curing type 1 diabetes, leading a team dedicated to advancing scientific discoveries. Additionally, he serves as Vice President and Senior Medical Officer at Novo Nordisk, a major global healthcare company, where he contributes his extensive industry knowledge to the development of new therapies, focusing on their safety and efficacy.\n\nDr. von Herrath's career is highlighted by significant contributions to immunology and drug development, effectively bridging the gap between academia and the pharmaceutical industry. He has been involved with the organ donor network (nPOD) for a long time, focusing on understanding T1D pathology. His work has been recognized with numerous awards, including the American Diabetes Association’s Outstanding Scientific Achievement Award in 2008, the German Diabetes Society’s Langerhans Award in 2014, and a lifetime achievement award from nPOD in 2018. These accolades underscore his impact on the field and dedication to improving the lives of those with type 1 diabetes.\n\nDr. Zornitza Stark\n\nAustralian Genomics\n\nProfessor Zornitza Stark is a clinical geneticist at the Victorian Clinical Genetics Services and Clinical Lead, Australian Genomics. She completed her medical studies at the University of Oxford, before training in paediatrics at the Royal Children’s Hospital in Melbourne, and in clinical genetics at VCGS. Zornitza is passionate about the integration of genomic testing into healthcare, particularly as a first-tier test for rare disease diagnosis in children. Since 2014, she has played a leadership role in numerous projects through Melbourne Genomics and Australian Genomics, as well as the Genomics Health Futures Mission, all aimed at accelerating rare disease diagnosis. She has co-authored over 220 papers, and has attracted over $60M in grant funding as investigator.\n\nDr. Said Ismail\n\nQPHI\n\nChief Scientific and Operations Officer, QPHI\n\nDr. Said Ismail holds a Ph.D. from the University of Oxford and an MSc from University College London (UCL). His experience extends over 25 years and involves research, education, clinical diagnostics, consultancy and management, including work at the Ludwig Institute for Cancer Research at UCL/UK, advisory roles at regional and international pharma/biotech companies, and a professor and director at the University of Jordan Medical School and the Clinical Genetic Diagnostics Laboratory at the University Hospital.\n\nIn 2015, Dr. Ismail Joined Qatar Foundation as the first full-time employee of the Qatar Genome Project and helped build a team and see the project grow into one of the largest population genomics initiatives in the region shedding light on the genetic makeup of Qataris as well as over 400 million genomically underrepresented Arabs.\n\nSaid also holds the position of an adjunct professor at both the Hamad Ben Khalifa University and Qatar University and is a board member at the Shoman Research Fund as well as the Transplant Immunology Research Centre of Excellence (TIREX) at Koç University, Istanbul/Turkey. He is also the first president and co-founder of the International Society on Aptamer Nanotechnology and an editorial board member in multiple international journals.\n\nDr. Ismail won several awards including the Said Foundation prize for young Arab researchers in the UK in 2001, the Ali Mango Award for distinguished Jordanian researchers in 2012 and the Shoman award for Arab researchers in biomedical sciences in 2013.\n\nDr. Ismail has special interest in promoting research among young Arab students. He launched one of the largest efforts to enhance the Arabic medical and scientific content on the internet; The “Bel-Arabi” initiative (http://www.bel-arabi.com) and he is also a Board member of the Phi Science Institute, which aims to encourage research among Arab youth (https://www.f6s.com/phiscienceinstitute).\n\nDr. Samih Alqawlaq\n\nIllumina\n\nSamih Alqawlaq is a Senior Clinical Sales Specialist at Illumina Middle East, with five years of experience in the Emerging Markets. He is a passionate genomics educator and an advocate for improved patient access to precision diagnostics.\n\nSamih has a solid scientific background and a track record in precision genomics sales and market development. Serving in the Middle East, Pakistan and Africa, Samih supports a broad range of applications, including Oncology, Rare Disease, and Infectious Disease\n\nPrior to joining Illumina, Samih worked at QIAGEN as a Genomics Field Applications Specialist. In this role, he became experienced in the hands-on aspects of NGS- and PCR-based assays.. During the COVID-19 pandemic, he worked with numerous public health units across MEA to set up NGS-based surveillance programs.\n\nSamih completed his PhD at the University of Toronto, Faculty of Medicine, in the department of Laboratory Medicine and Pathobiology. He also completed a master’s degree at the University of Waterloo, School of Pharmacy, with a focus on gene therapy and nanotechnology.\n\nWhen he is not traveling to speak with customers, Samih mentors graduate students from his alma mater. He believes that professionals should give back to their community and promote an environment of mentorship and collaboration.\n\nDr. Edison Liu\n\nJackson Laboratory\n\nEdison Liu, M.D. is professor and special fellow of The Jackson Laboratory (JAX), an independent research institute focused on complex genetics and functional genomics situated in Maine, Connecticut, and California. Previously, he was president and CEO of The Jackson Laboratory, and Director of its NCI designated Cancer Center. Before that, he was the founding executive director of the Genome Institute of Singapore, the president of the Human Genome Organization (HUGO), the scientific director of the National Cancer Institute's Division of Clinical Sciences in Bethesda, Md., and professor of medicine, genetics, biochemistry, and epidemiology at the University of North Carolina, Chapel Hill. Dr. Liu is an international expert in cancer biology, systems genomics, human genetics, molecular epidemiology and translational medicine with a focus on human breast cancer. He has authored over 340 scientific papers, reviews and books, and is a frequent commentator on the impact of technologies in the biosciences and medicine. He obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University; his advanced training in medicine and oncology at Washington University, St. Louis, and Stanford, and post-doctoral training in molecular oncology at the University of California at San Francisco. Dr. Liu has received numerous awards, and is an elected member to the American Society of Clinical Investigation, a foreign member of the European Molecular Biology Organization, and a Fellow of the American Association for the Advancement of Science (AAAS).\n\nDr. Mitchell Stotland\n\nSidra Medicine\n\nDr. Mitchell Stotland is Vice Chair, Department of Surgery, Division Chief of Plastic and Craniofacial Surgery, and Medical Director, Perioperative Services at Sidra Medicine in Doha, Qatar. Completed medical school and plastic surgery residency at McGill School of Medicine in Montreal, Canada (1989), and craniofacial surgery fellowship at the University of California, Los Angeles (1997). Practiced at Dartmouth Hitchcock Medical Center and the Children’s Hospital at Dartmouth (1997-2014), founding a multidisciplinary craniofacial anomalies program in 2000. 2007, obtained Master of Science degree in Evaluative Clinical Sciences from the renowned Dartmouth Institute. 2007, founded the Tanzer Plastic Surgery Symposium.\n\n2014, became founding division chief of Plastic and Craniofacial Surgery at Sidra Medicine, appointed Associate Professor of Clinical Surgery at Weill Cornell Medical College – Qatar; 2019 as Medical Director, Perioperative Services, and 2021 as Vice Chair, Department of Surgery, Sidra Medicine. Has introduced a variety of new and complex plastic surgical procedures – and a multidisciplinary approach to craniofacial care – to Qatar. May 2023, founded and chaired the Inaugural “Artificial Intelligence and Medicine – Bringing Digital Breakthroughs to the Bedside” symposium at Sidra Medicine.\n\nArea of clinical interest includes cleft lip/cleft palate, isolated and syndromic forms of craniosynostosis, facial trauma, and total ear reconstruction. Basic science research focuses on the assessment and measurement of facial deformity including through the development of novel machine learning models (lead PI on QRDI grant 2021-2024). June-September 2023 Dr. Stotland completed the MIT Professional Education course entitled “No Code AI and Machine Learning. Building Data Science Systems”.\n\nDr. Paul Franks\n\nLund University\n\nPaul W. Franks PhD MPhil MS FTOS is Professor of Genetic Epidemiology at Lund University, Sweden and an Adjunct Professor at the Harvard School of Public Health, Boston, MA. Paul trained at the University of Cambridge and the NIH in human metabolism and cardiovascular physiology, as well as classical biostatistics and genetic epidemiology. He was head of the Novo Nordisk Foundation Department of Translational Medicine (2021-2024) and Deputy Director of the Lund University Diabetes Center (2016-2021). He currently co-chairs the ADA/EASD Precision Medicine in Diabetes Initiative and the NIDDK Heterogeneity of Diabetes Initiative. His research uses multimodal AI to explore interactions among human biological variation, lifestyle, and medications to develop precision prediction and diagnostic subclassification models. Paul has spearheaded the development of consensus standards, guidelines, and translational frameworks for precision medicine that are now globally adopted by leading institutions.\n\nDr. Emanuele Bosi\n\nTrialNet Network\n\nHe is a physician scientist and Professor of Endocrinology at Università Vita-Salute San Raffaele. He serves as Head of the General Medicine, Diabetes, and Endocrinology Department, and Director of both the Diabetes Research Institute and the Post-Graduate School of Endocrinology at Ospedale San Raffaele. Bosi graduated in Medicine from the University of Milan, where he also specialized in diabetes, metabolic diseases, and clinical immunology. His research focuses on diabetes prediction, prevention, and new treatments, including technologies for blood glucose monitoring. He leads the TrialNet Clinical Center at San Raffaele, part of an NIH-funded network conducting trials in type 1 diabetes. Bosi is a member of several scientific societies, an editorial board member for various journals, and a scientific advisor to numerous pharmaceutical and biotech companies. He has published over 150 scientific papers.\n\nDr. Peter Goodhand\n\nAG4GH\n\nChief Executive Officer, Global Alliance for Genomics and Health, President, GA4GH Inc. Toronto, Canada\n\nPeter Goodhand is a leader in the global health sector, holding senior executive and board member positions in the health research advancement community.\n\nHe currently serves as the Chief Executive Officer of the Global Alliance for Genomics and Health (GA4GH) and President of GA4GH Inc. The Global Alliance for Genomics and Health (GA4GH) is a policy-framing and technical standards-setting organization, seeking to enable responsible genomic data sharing within a human rights framework. GA4GH Inc. is a non-profit corporation based in Canada that supports the long-term work of the broad-based Alliance.\n\nMr. Goodhand previously served as President of the Ontario Institute for Cancer Research (OICR) and President and CEO of the Canadian Cancer Society. Before joining the charitable sector, he had a 20-year career in the global medical technology industry.\n\nMr. Goodhand is currently Co-Chair of the International Health Cohort Consortium (IHCC) and serves on the governance boards of Global Genes and several national and international advisory bodies.\n\nDr. Camillo Ricordi\n\nUni. Of Miami\n\nCamillo Ricordi, M.D. is Professor of Surgery, Medicine, Biomedical Engineering, Microbiology and Immunology at the University of Miami, Florida, where he serves as Director of the Cell Transplant Center and Director Emeritus of the Diabetes Research Institute\n\nRicordi has received numerous honors and awards, including the World Prize in Surgery (University of Geneva), the Outstanding Scientific Achievement Award by the American Diabetes Association, was Knighted by the President of the Republic of Italy. He was inducted into the National Academy of Inventors USA, for contributing outstanding inventions that have made a tangible impact on quality of life, economic development, and welfare of society, and was appointed to the Supreme Council of Health (Consiglio Superiore di Sanita’) by the Ministry of Health of Italy. In 2023, he was awarded the Leonardo Da Vinci Award (co-shared with Nobel Prize winners Yamanaka and Semenza - Taormina TaoBuk) and the Venice Golden Lion Award.\n\nRicordi contributed over 1,170 publications, that received over 54,000 citations, has 114 H-index.\n\nIn 2022 he published the best-seller book “IL CODICE DELLA LONGEVITÀ SANA” now available also in its English edition: “THE HEALTHSPAN CODE” (Amazon.com).\n\nDr. Farhan Naim\n\nFarhan read Human Biology at King’s College London, graduating with a BSc honors degree in 2001. Upon graduation, he joined the phase I clinical research organization industry, holding multiple Clinical Trial Associate posts including at the world’s largest CRO, IQVIA. Having gained a solid foundation in the principles of clinical trial conduct, management, regulation and delivery, he crossed over into the English National Health Service as Oncology Clinical Trials Practitioner at the Imperial College Healthcare NHS trust in 2003. Here he worked alongside world-renowned investigators, supporting the delivery of late-phase clinical trials in breast, lung, colorectal and urological cancers. In 2010, Farhan was appointed as Oncology Clinical Trials Portfolio Manager at the Royal Free London NHS Foundation Trust, one of the leading academic health centers in the UK. He obtained an MSc in Clinical Oncology at the University of Birmingham in 2011 with a thesis entitled ‘Breast cancer patient perceptions in undergoing additional biopsies for research’. Remaining at the Royal Free, Farhan was subsequently appointed as Deputy Director of Research and Development in 2013 and then as Director of Research and Development in 2018 where he led the organization’s clinical research agenda, setting strategy and overseeing operations. Highlights of his tenure here include the development of a £5M NIHR funded clinical research facility, propelling the organization into a national top-10 spot for patients recruited into clinical trials and leading the development and execution of a highly acclaimed 5-year clinical research strategy. Farhan relocated to Doha in February 2024 and is currently heading the research PMO at Sidra Medicine.\n\nLinkedIn: https://www.linkedin.com/in/farhan1978/\n\nDr. Manuela Battaglia\n\nINNODIA iVZW\n\nManaging Director of the INNODIA iVZW\n\nDr. Battaglia is an immunologist by training and became a scientist to transform patients’ lives. She spent 20 productive years in academic research focused on understanding the pathogenesis of type 1 diabetes.\n\nWhen she was Vice-Director of the San Raffaele Diabetes Research Institute in Milano (Italy), she decided to enter into a different path to reach a higher impact on patients and society. She then spent the following 4 years in leading managerial positions in international organizations focused on reducing the waste of talent, research, and funds in the biomedical field for the benefit of patients.\n\nShe will now capitalize on her scientific and managerial competencies to take INNODIA to the next level and reach its ultimate goal: tackling type 1 diabetes.\n\nProf. Khalid Fakhro\n\nSidra Medicine\n\nProf. Khalid Fakhro / Chair Khalid Fakhro is the Chief of Research and Director of the Precision Medicine Program at Sidra Medicine, the largest tertiary care women and children hospital in Qatar. Prof. Khalid Fakhro / ChairFakhro leads the Laboratory of Genomic Medicine, which focuses on bringing emerging genomic technologies from the lab close to the patient’s bedside. Over the past decade, his group has sequenced thousands of genomes from patients and volunteers across the Middle East, leading gene discovery efforts for a wide range of rare disorders, as well as landmark studies on population structure, genome structural variation, and the role of Islamic ethics in genome research. To date, his lab has been awarded competitive grants exceeding $7m to study genome structure and the genetic etiology of rare diseases and Autism, and their discoveries have featured in high-impact journals worldwide. In addition to research and hospital duties, Prof. Khalid Fakhro / Chair Fakhro serves multiple leadership roles in Qatar’s growing biomedical ecosystem, including as a Board Member of the Qatar Precision Medicine Institute, and Adjunct Faculty at both Weill-Cornell Medical College and Hamad Bin Khalifa University, where he teaches and supervises Masters and Ph.D. students in genomics and precision medicine.\n\nDr. Wan Yue\n\nA* STAR Institute\n\nYue Wan is the Deputy Executive Director of the Genome Institute of Singapore, A*STAR. She received her B.Sc in Cell Biology and Biochemistry from the University of California, San Diego. She obtained her Ph.D. in Cancer Biology from Stanford University, USA, under the mentorship of Howard Y. Chang. During her Ph.D., she developed the first high-throughput method for probing RNA structures genome-wide. Yue is a recipient of the NSS-PhD scholarship from Agency for Science, Technology, and Research (A*STAR) in Singapore. She was a Society in Science- Branco Weiss Fellow, EMBO Young Investigator, and CIFAR-Azrieli Global Scholar. Yue is also a recipient of the Young Scientist Award and L’Oreal-UNESCO for Women in Science, Singapore National Fellowship. Recently, Yue is also a participant of the international Welcome Leap RNA Readiness and Response program. Yue is interested in studying functional RNA structures and developing new versions of RNA as vaccines and therapeutics.\n\nDr. Raghib Ali\n\nOur Future Health\n\nProfessor Raghib Ali is the CEO, Chief Investigator and Chief Medical Officer of Our Future Health; a Clinical Epidemiologist at the University of Cambridge; a Consultant in Acute Medicine at the Oxford University Hospitals NHS Trust; and Honorary Consultant with the Office for Health Disparities and Improvement.\n\nHe graduated from Cambridge University and has been awarded postgraduate degrees in Epidemiology and Public Health from the Universities of London, Cambridge and Oxford and is a Fellow of the Royal College of Physicians. He has been involved in population health research since 2004 nationally and globally, working firstly on UK Biobank, then leading studies of cancer incidence by ethnic group in England and India from 2005 to 2013 and established the UAE Healthy Future Study, in 2014, for which he is the principal investigator.\n\nHe was awarded an OBE in the Queen’s Birthdays Honours 2022 for services to the NHS and the Covid-19 response and elected as an Honorary Fellow of the Faculty of Public Health, ‘the highest accolade the Faculty can bestow and is awarded to those who have given exceptional service to the science, literature or practice of public health’ in April 2023.\n\nDr. Haydar Frangoul\n\nTristar Cent. Children's H.\n\nDr. Haydar Frangoul, MD, MS. is the Director of the Pediatric Stem Cell Transplant program at the Sarah Cannon Research Institute and Tristar Centennial Children's Hospital and in Nashville Tennessee. Dr Frangoul completed his MD degree at the American University of Beirut followed by Pediatric residency at Duke University. He then went to complete a fellowship in Pediatric Hematology/Oncology and Stem Cell Transplant at the University of Washington and the Fred Hutchinson Cancer Center. He was the Carolyn Perot Rathjen Endowed Professor of Pediatric Hematology/Oncology at Vanderbilt University until 2015 when he joined Sarah Cannon Research Institute to lead the Pediatric Stem Cell Transplant Program.\n\nDr Frangoul had leadership positions in the Children Oncology group, and Pediatric Blood and Marrow Transplant Consortium. His primary interest is allogeneic stem cell transplant using an alternative donor sources especially for non-malignant diseases. Dr Frangoul has authored or co-authored more than 140 peer reviewed manuscripts. He has been an invited speaker at numerous national and international conferences. He is the lead investigator for the clinical trial using CRISPR-Cas9 gene editing for patients with sickle cell disease.\n\nDr. Medhat Askar\n\nMedhat Askar, MD, PhD, MSHPE, FRCPath, F(ACHI), D(ABMLI), HCLD(ABB) is the Associate Vice President for Clinical Affairs and Professor of Immunology at the College of Medicine at Qatar University. He also serves as the Division Head of Clinical Immunology at the Department of Laboratory Medicine and Pathology at Hamad Medical Corporation, Doha, Qatar, a Clinical Professor in the Department of Medical Education at Texas A&M Health Science Center College of Medicine, Bryan, TX and the Advisor for the Clinical Services at The National Marrow Donor Program, Minneapolis, MN. Before Joining Qatar University he served as the Director of Transplant and Genomics Core, COVID-19 Testing and Stem Cell Processing Laboratories at Baylor University Medical Center, Dallas, TX and Clinical Consultant in the Department of Laboratory Medicine of Memorial Sloan Kettering Cancer Center, New York, NY.\n\nCurrently Dr. Askar is the Treasurer of The Transplantation Society (TTS); Treasurer of The Association of Medical Laboratory Immunologists (AMLI); Board Member of the Worldwide Network for Blood & Marrow Transplantation; Councilor of the International HLA & Immunogenetics Workshops; Chair of the Histocompatibility Committee of the Foundation for Accreditation on Cellular Therapy (FACT) and member of the Laboratory Practice Committee of the International Society of Cell and Gene Therapy (ISCT). Previously he served as President of The American Society for Histocompatibility and Immunogenetics (ASHI); President of The American College of the Histocompatibility and Immunogenetics (ACHI), a member of the Board of Directors and the Executive Committee of the United States United Network for Organ Sharing (UNOS), and a Board Member of The Arab Society of Histocompatibility & Immunogenetics (ARSHI). I published and lectured on various topics of transplant Immunology, cell and gene therapy, quality systems and accreditation, health professions education and leadership in major transplant conferences and leading academic institutions across 6 continents.\n\nDr. Ian Pople\n\nDr. Ian Pople is a graduate of Sheffield University, UK and did his neurosurgical training in Leeds, Great Ormond Street Hospital in London, Bristol and Memphis USA where he did his fellowship in Pediatric Neurosurgery at Le Bonheur Children’s Hospital and St Jude Children’s Research Hospital.\n\nPrior to joining Sidra Medicine as the Chief of Neurosurgery, Dr. Pople was Senior Pediatric Neurosurgeon at Bristol Royal Hospital for Children, UK, where he led the development of the Epilepsy Surgery and SDR services for Children and performed over 2000 pediatric neurosurgical procedures. For the first 20 years of his career he was a consultant neurosurgeon at Frenchay Hospital in Bristol dealing with over 500 cases a year including all types and head and spinal trauma.\n\nDr Ian has a specialist interest in complex hydrocephalus, neuro-endoscopy, epilepsy and brain tumors. Throughout his career as a neurosurgeon he has maintained a strong interest in clinical research with over 70 publications to date and serving on the Executive Commottee of the Society for Research into Hydrocephalus and Spina Bifida for 20 years. He has been leading projects into new treatments for hydrocephalus in premature infants in the UK and more recently at Sidra Medicine in Qatar, where he was awarded a Research Grant.\n\nDr. Karolina Kobus\n\nDr. Kobus is a molecular geneticist with over 15 years of expertise spanning molecular biology, reproductive genetics, prenatal diagnostics, oncogenetics, and pharmacogenetics. Currently, she serves as an active Precision Genomics consultant, spearheading the establishment of innovative genetic services and advocating for awareness and preventive strategies. She champions the concept of conducting highly specialized testing locally in the Middle East, aiming not only to enhance outcomes, optimize healthcare efficiency, and generate cost savings but also to foster the development of local talents.\n\nDr. Kobus has previously held positions at esteemed governmental institutions including the Max Planck Institute for Molecular Genetics and the Human Genetic Department at Charite University Hospital in Germany, as well as the National Genetic Centre at the Ministry of Health in Oman. In these roles, she conducted comprehensive data analysis and interpretation for genetic cases utilizing cutting-edge technologies such as Array CGH, Whole Exome Sequencing, and Clinical Genomics.\n\nAdditionally, Dr. Kobus actively assists healthcare systems in promoting themselves through scientific conferences and educational series.\n\nDr. Samir Gupta\n\nSamir Gupta is a Professor of Neonatology at Durham University, UK, and a Fellow at the National Perinatal Epidemiology Unit, Oxford University, United Kingdom. He is the Division Chief of Neonatology, a Quaternary Care neonatal unit at Sidra Medicine (Children’s Hospital), Qatar.\n\nHe is a Fellow of Royal College of Pediatrics and Child Health and Fellow of Royal College of Physicians of Ireland. He is member of European steering group of the Neonatologist performed echocardiography (NPE). He is founder and chair of the Neonatologist with interest in Cardiology & Hemodynamics in the UK and has now successfully established Qatar NPE training program at Sidra Medicine in Doha, Qatar.\n\nHe is a member of several scientific organizations, including the European Society for Pediatric Research (ESPR) and Society for Pediatric Research (USA). He has authored over 150 articles in indexed peer reviewed journals and books. He has been invited guest editor high impact journals.\n\nHe is Chief investigator of Baby-OSCAR trial on patent ductus arteriosus (PDA), (https://www.npeu.ox.ac.uk/baby-oscar). He established 1st global Annual international neonatal cardiology & hemodynamics conference in UK in 2010, which is successfully running to date (www.neonatalcardiology.co.uk)\n\nHe has established Neonatal hemodynamics program at Sidra Medicine with a team of clinicians, that has significantly improved neonatal outcomes in surgical, complex and sick newborn infants. He works collaboratively with Pediatric cardiology and fetal medicine division to improve the care of complex cardiac patients admitted to the NICU. Currently, he is working to set up the ‘Cardiac ICU on NICU’’ and expanding the NPE training program internationally. He also advises on various international forums on cardio-respiratory disorders and management and is international expert in this field.\n\nDr. Chantal Mathieu\n\nEASD\n\nProfessor of Medicine at the Katholieke Universiteit and Chair of Endocrinology at the University Hospital Gasthuisberg Leuven, Belgium\n\nChantal Mathieu is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research. Her basic research work focuses on pathogenesis and prevention of type 1 diabetes. Prof. Mathieu’s clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes have made her a speaker in international fora. Prof. Mathieu coordinates the European clinical trial network for interventions in type 1 diabetes ‘INNODIA’ and the European project ‘EDENT1FI’ on screening for type 1 diabetes. Prof. Mathieu is president of EASD and vice-president of the European Diabetes Forum.\n\nDr. Tawfeg Ben Omran\n\nDr. BEN-OMRAN is a senior consultant and Division Chief, Genetic and Genomic Medicine at Sidra Medicine and Hamad Medical Corporation. He is a Professor at Weill Cornell Medical College, Qatar & New York-USA. He is also a Distinguished Visiting Scientist at Boston Children’s Hospital-USA.\n\nHe contributes to the body of published knowledge in clinical and metabolic genetics, with over 200 published articles in peer reviewed journals, book chapters and abstracts. He is reviewer for many clinical genetics journals.\n\nHe is an active clinical researcher, collaborating on projects with local, regional & international communities. He is a lead primary investigator in many high profile research projects & clinical trials.\n\nDr. Essam Abdelalim\n\nDr. Abdelalim holds the position of Senior Scientist at QBRI and serves as an Associate Professor at HBKU. His academic journey includes obtaining a PhD in Medical Science from Shiga University of Medical Science in Japan, followed by a role as an Assistant Professor at the same institution.\n\nSince March 2014, Dr. Abdelalim has been instrumental in establishing Qatar's pioneering pluripotent stem cell program at QBRI, with a primary focus on diabetes research. His research endeavors utilize human pluripotent stem cells to decipher the mechanisms behind diabetes development while striving to produce functional pancreatic cells for prospective therapeutic applications. His team has successfully generated over 100 iPSC lines sourced from a diverse pool of patients with both monogenic and polygenic forms of diabetes. Furthermore, they have innovated novel methodologies for differentiating stem cells into insulin-secreting and insulin-target cells.\n\nDr. Abdelalim chairs the Steering Committee of the Harvard Stem Cell Institute (HSCI)-QBRI Agreement, overseeing the collaborative diabetes/stem cell program between HSCI and QBRI. He also serves on the editorial boards of esteemed journals like \"Stem Cells and Development\" and \"Frontiers in Endocrinology.\" He has authored over 70 articles in reputable scientific journals. Dr. Abdelalim's career is marked by numerous research grants and prestigious awards. In addition, as an educator, he teaches the \"Stem Cell Biology\" course at HBKU. He has mentored 15 graduate students at HBKU, contributing significantly to their international recognition for outstanding work.\n\nDr. Mohammad Karim\n\nChief, Division of Hematology/Immunology/Transfusion, at Sidra Medicine and Clinical Professor in Immunopathology, Qatar University. Yousuf studied medicine at Cambridge University, with clinical training at Guy’s & St Thomas’ Hospitals, qualifying in 1993 with Distinctions in Medicine and Pathology. He was a Clinical Lecturer in Immunology at King’s College London 1998-2004, then Consultant Immunologist at Surrey Pathology Services 2004-18 and Clinical Lead in Immunology at Guy's & St Thomas' Hospitals, London 2006-14. He worked for 25 years in the UK National Health Service, before moving to establish the Diagnostic Immunology Laboratory at Sidra in 2018. His early work studied novel diagnostic methods and treatments for SLE, and his current research concerns early recognition and diagnosis of primary and secondary immunodeficiency. He has authored 90 publications and chapters, and received grant awards in autoimmunity and immunodeficiency, totaling £2.5 million. He was Chair of the Clinical Immunology Committee of the British Society for Allergy and Clinical Immunology 2014-17, an Expert Member for the NICE Quality Standards on Drug Allergy in 2015, on the Guidelines Committee of UK-Primary Immunodeficiency Network 2016-18, and is the Country Advisor for the Royal College of Pathologists for Qatar. In 2018, he was the senior author on UK recommendations for hypogammaglobulinemia secondary to B-cell therapies, and has a current grant studying immunodeficiency after rituximab in autoimmunity. He is the co-Lead of the Sidra Immune Dysregulation Clinical Research Program.\n\nDr. Nicolas Encina\n\nICoNS Consortium\n\nNic Encina is the Director of Strategy & Cofounder of the Precision Population Health program at Ariadne Labs, Harvard School of Public Health, and Brigham & Women’s Hospital, and he is also Executive Director & Cofounder of the International Consortium on Newborn Sequencing (ICoNS), which holds an annual conference and is spearheading the harmonization of learnings across global programs. Nic is a successful entre- and intra-preneur, having started a series of successful software companies, biotech companies, and many successful intrapreneurial ventures, such as an innovation lab for PerkinElmer, a Harvard research program, and flagship product lines for publicly traded companies. Nic holds graduate degrees in Stem Cell Biology, Computer Science, and an MBA from Yale, with his graduate work conducted in the BLAST lab of Washington University Medical School, as part of the Human Genome Project.\n\nDr. Richard Oram\n\nProfessor Richard Oram is a Diabetes UK Harry Keen Fellow specializing in Type 1 diabetes at the Institute of Biomedical and Clinical Science and NIHR Exeter Clinical Research Facility. Richard finished his Diabetes UK funded PhD on endogenous insulin production in type 1 diabetes in 2014, he showed that most people with type 1 diabetes still make small amounts of their own insulin. Funded by JDRF, he continues to study the biology of beta cell loss in type 1 diabetes and the impact of persistent beta cell function on complications, including hypoglycemia. His Harry Keen fellowship and the Helmsley Charitable Trust fund Richard and Tim Tree (KCL) to study the causes of a rare subtype of extremely early onset type 1 diabetes - diagnosed under the age of 1 year. This overlaps with work with Sarah Richardson, Noel Morgan, Andrew Hattersley and Tim McDonald to better define endotypes of type 1 diabetes.\n\nWith other collaborators, has developed a cheap, simple method to assess genetic risk in type 1 diabetes – a T1D genetic risk score (T1D GRS). He has shown this can be used as a diagnostic test to differentiate type 1 and type 2 diabetes, and with Kash Patel has shown it can be used to identify monogenic diabetes. Collaborating with Bill Hagopian (PNRI, Seattle), he recently improved the T1D GRS to include more HLA alleles and their interactions.\n\nRichard is testing the utility of the T1D GRS for prediction of Type 1 diabetes. Funded by JDRF, with Bill Hagopian, he is investigating combining genetic information with longitudinal biomarkers to better predict type 1 diabetes and other autoimmune diseases from birth in the NIH funded TEDDY study. Richard is working with Bill Hagopian to test a newborn genetic screen with autoantibody monitoring follow up to prevent childhood diabetic ketoacidosis in the CASCADE study. Recently, Richard spent a period of his training at the University of Alberta with the world leading clinical islet transplant and renal transplant programs.\n\nDr. Younes Mokrab\n\nProfessor Younes Mokrab is Principal Investigator, acting director of Population Genomics Medicine and Lead of Neuroscience Research Program at Sidra Medicine. Also, he is adjunct Professor of Biomedical Sciences at Qatar University. Prof. Mokrab obtained a BSc in Genetics from the University of Sheffield, UK (2003), a PhD in Bioinformatics from Prof. Tom Blundell lab, University of Cambridge, UK (2007), followed by a postdoctoral fellowship from Prof. Mark Sansom Lab, University of Oxford (2010). Next, he moved to the pharmaceutical industry, initially Lonza Biologics performing in silico bio-pharmaceuticals engineering and subsequently Eli Lilly where he led research in early-stage drug discovery in various areas of neuropsychiatry. Upon joining Sidra in 2015, Dr Mokrab helped establish research programs in population and medical genetics in particular in neurodevelopmental disorders, co-founded the Qatar Genome Program Research Consortium and established links with various international consortia. His lab’s expertise lies in genomics/bioinformatics and data science especially long-read sequencing and multiomics. Over the past decade, his group has sequenced hundreds of genomes for patients and family members across the Middle East, leading gene discovery using state of the art technologies, as well as landmark studies on population structure, genome references and transcriptomics. Prof. Mokrab serves on multiple leadership roles at Sidra and outside and has co-chaired and spoke at multiple national and international conferences. Dr Mokrab is a co-author of > 50 publications in top tier including Nature and Cell journals and is the recipient of multiple grants and awards."
    }
}